News & Updates
Filter by Specialty:

Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
For patients with stage III or IV melanoma, treatment with pembrolizumab both before and after surgical resection leads to longer event-free survival than treatment with pembrolizumab only after the procedure, according to the results of a phase II study.
Neoadjuvant–adjuvant bests adjuvant-only pembrolizumab in advanced melanoma
14 Mar 2023
Vitamin D supplementation touted for dementia prevention in high-risk individuals
Vitamin D may offer brain boosting benefits, with a large study providing evidence that vitamin D supplementation exerts some effect in the prevention of dementia.
Vitamin D supplementation touted for dementia prevention in high-risk individuals
13 Mar 2023
Outpatient oritavancin reduces hospitalization in acute uncomplicated cellulitis
Outpatient oritavancin therapy for patients with acute uncomplicated cellulitis results in a decrease in 30-day hospital readmissions or admissions when compared with inpatient standard of care (SoC), a recent study has shown.
Outpatient oritavancin reduces hospitalization in acute uncomplicated cellulitis
13 Mar 2023
STELLAR trial offers hope for rare heart-lung disorder
The phase III STELLAR trial lives up to its name, delivering stellar results and offering hope for patients with pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening disorder affecting the heart and lungs, by adding sotatercept – a novel first-in-class activin signalling inhibitor – to background therapy.
STELLAR trial offers hope for rare heart-lung disorder
13 Mar 2023
Short-term risk of certain cancers similar in RA, PsA patients treated with JAK, TNF inhibitors
For patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA), initiation of Janus kinase (JAK) inhibitor treatment does not carry a higher short-term risk of cancer, with the exception of nonmelanoma skin cancer (NMSC), as compared with initiation of biological disease-modifying antirheumatic drugs (bDMARDs) including tumour necrosis factor (TNF) inhibitors, according to a study.